Pharmacogenetics (PGx) and Pharmacokinetics Research Group
Our group investigates the effect of genetic variants and pharmakokinetic factors on drug levels, efficacy and side effect to enhance the efficacy and tolerability of of psychoharmacologic drugs. Pharmacogenetics seeks to tailor treatments to individual genetic makeup. This personalized approach promises enhanced drug efficacy and safety while minimizing adverse reactions. Pharmacokinetics research, on the other hand, focuses on understanding how the body processes drugs. By studying factors like absorption, distribution, metabolism, and excretion, researchers aim to optimize drug dosing regimens. This knowledge can lead to more precise dosage adjustments based on factors such as age, gender, and genetic variations, ultimately improving therapeutic outcomes. Also, drug interactions play a vital role in the pharmacokinetics of a drug. How can they be avoided? What databases can be used and how can they be optimized? Overall, the goals of pharmacogenetics and pharmacokinetics research group include maximizing drug efficacy, minimizing adverse effects, and advancing personalized medicine to provide tailored treatments that maximize patient benefits.
Current group members:
Prof. Dr. Martina Hahn (Group leader)
Dr. Andreas Eckert (Post-doc)
Fabian Sattaf (MD)
Anna Böttcher (DMD)
Liv Illgner (MD)
Carolin Görnert (MD student)
Former Members:
Amelie Frantz (DMD)
Selected Publications:
Eckert A, Frantz A, Scherf-Clavel M, Weber H, Unterecker S, Reif A, Hahn M. Divergent Phenotypes, Actionable Genotypes, and Phenoconversion in a German Psychiatric Inpatient Population: Results from the FACT-PGx Study. Journal of Exploratory Research in Pharmacology 2023 vol. 000(000) | 000–000 Epub
DOI: 10.14218/JERP.2023.00042
Scherf-Clavel M, Weber H, Unterecker S, Frantz A, Eckert A, Reif A, Deckert J, Hahn M. The Relevance of Integrating CYP2C19 Phenoconversion Effects into Clinical Pharmacogenetics. Pharmacopsychiatry. 2024 Feb 14. doi: 10.1055/a-2248-6924. Epub ahead of print. PMID: 38354747.
Sattaf F, Scherf-Clavel M, Unterecker S, Reif A, Hahn M. Recommendation for a Therapeutic Reference Range of Cariprazine-A Short Communication. Ther Drug Monit. 2023 Nov 14. doi: 10.1097/FTD.0000000000001152. Epub ahead of print. PMID: 38018849
Stuhec M, Hahn M, Taskova I, Bayraktar I, Fitzgerald I, Molitschnig L, Tatarević A, Lindner N, Agnoletto, N, Alves da Costa F. Clinical pharmacy services in mental health in Europe: a commentary paper of the European Society of Clinical Pharmacy Special Interest Group on Mental Health. International Journal of Clinical Pharmacy. Epub ahead of print Sep. 2023 https://doi.org/10.1007/s11096-023-01643-4
Hahn, M, Stuhec, M, Alves da Costa F. Overview of this issue: “clinical pharmacy impacting mental health delivery and outcomes. International Journal of Clinical Pharmacy (2023) 45:1025–1026. https://doi.org/10.1007/s11096-023-01654-1
Eckert A, Frantz A, Reif A, Hahn M. Wissen Akzeptanz Einstellung von Ärzten. Nervenheilkunde 2023; 42(07/08): 459-466 DOI: 10.1055/a-2050-0116
Hahn M, Roll SC. The role of phenoconversion in the pharmacogenetics of psychiatric psychiatric medication. Pharmacogenomics 2023. Epub ahead of print: https://doi.org/10.2217/pgs-2023-0100
Scherf-Clavel M, Frantz A, Eckert A, Weber H, Unterecker S, Deckert J, Reif A, Hahn M. Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort study. International Journal of Clinical Pharmacy (2023) 45:1107–1117
https://doi.org/10.1007/s11096-023-01588-8
Hahn M, Roll SC. The relevance of long-acting injectables in the treatment of schizophrenia. Lancet Psychiatry. 2023 Jan 27:S2215-0366(23)00033-0. doi: 10.1016/S2215-0366(23)00033-0. Epub ahead of print. PMID: 36716760.
Roll SC, Hahn M. Rates of Divergent Pharmacogenes in a Psychiatric Cohort of Inpatients with Depression—Arguments for Preemptive Testing. Journal of Xenobiotics. 2022; 12(4):317-328. https://doi.org/10.3390/jox12040022
Hahn M, Roll SC. A Collaborative Approach in Pharmacogenetic Testing: Actionable Genotypes of Antidepressants and Their Avoidance in a Retrospective Study. J Explor Res Pharmacol 2023;8(1):4-11 doi: 10.14218/JERP.2022.00054.
Hahn M, Roll SC. The Influence of Pharmacogenetics on the Clinical Relevance of Pharmacokinetic Drug-Drug Interactions: Drug-Gene, Drug-Gene-Gene and Drug-Drug-Gene Interactions. Pharmaceuticals (Basel). 2021;14(5):487. Published 2021 May 20. doi:10.3390/ph14050487
Toto, S., Hefner, G., Hahn, M. et al. Current use of anticholinergic medications in a large naturalistic sample of psychiatric patients. J Neural Transm 2021 Feb;128(2):263-272.https://doi.org/10.1007/s00702-020-02298-5
Hefner G, Hahn M, Toto SM, Roll SC, Hiemke C, Wolff J, Klimke A. Pharmacodynamic Drug-Drug Interactions of QT-prolonging drugs in hospitalized psychiatric patients. J Neural Transm 2021 Feb;128(2):243-252. doi: 10.1007/s00702-020-02291-y
Hahn M, Müller DJ, Roll SC Frequencies of Genetic Polymorphisms of Clinically Relevant Gene-Drug Pairs in a German Psychiatric Inpatient Population Pharmacopsychiatry 2020; 53: 1–9
Hefner G, Hahn M, Toto S, Hiemke C, Roll SC, Wolf J, Klimke A. Potentially inappropriate medication in older psychiatric Patients. Eur J Clin Pharmacol. 2021 Mar;77(3):331-339. doi: 10.1007/s00228-020-03012-w.Epub 2020 Oct 8.
Schoretsanitis G, Baumann P, Conca A, Dietmaier O, Giupponi G, Gründer G, Hahn, M, Hart X, Havemann-Reinecke U, Hefner G, Kuzin M, Mössner R, Piacentino D, Steimer W, Zernig G, Hiemke C. Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotic Drugs, Therapeutic Drug Monitoring: February 2021;43(1):79-102. doi: 10.1097/FTD.0000000000000830
Hefner, G., Wolff, J., Hahn, M. et al. Prevalence and sort of pharmacokinetic drug–drug interactions in hospitalized psychiatric patients. J Neural Transm (2020). https://doi.org/10.1007/s00702-020-02214-x
Bättig V, Roll SC, Hahn M. Pharmacogenetic Testing in Depressed Patients and Interdisciplinary Exchange between a Pharmacist and Psychiatrists Results in Reduced Hospitalization Times. Pharmacopsychiatry 2020; 53:185-192 DOI https://doi.org/10.1055/a-1096-1171